

September 3, 2019

Press release

EFPIA Japan
(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Patient Organization Support Program “PASE” Third “PASE AWARD” winners decided

EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) has made its third PASE AWARDS, selecting patient groups that particularly contribute to the evolution of Japan’s patient advocacy and offering grants totaling 1.45 million yen. These grants have been made as part of “PASE (Patient Advocacy Support by EFPIA Japan (hereinafter, ‘PASE’))”. For the third year, "patient group activities for issues that have not yet been resolved in disease prevention, diagnosis, and treatment" was selected as the application theme. Recruitment of patient organizations' action plans started in May. This year the “Grand Award” has been given to two groups, and the “Honor Award” has been given to three groups, from the total 15 groups that applied to this program by July 26.

PASE AWARD winning organizations

Award	Award winning organization	Overview of application/proposal	Grant (JPY)
Grand Award	HAEJ	<ul style="list-style-type: none"> • Conduct surveys with HCP to find unmet needs for pediatric and adolescent patients. • Focus group event based on survey results. 	500,000
Grand Award	Cancer Forum Yamanashi	Conduct “Survey of current status of vaccination” with a view to preventing non-disease after hematopoietic stem cell transplantation.	500,000
Honor Award	Kirara (Breast cancer)	<ul style="list-style-type: none"> • Conduct SE surveys associated with cancer treatment 	150,000
Honor Award	Lung one-step	<ul style="list-style-type: none"> • Implement educational activities regarding asbestos-derived lung cancer 	150,000
Honor Award	Living with Cancer	Establish a site for the purpose of networking for patient group such as cancer and intractable diseases and care required by patients and families	150,000

EFPIA Japan

Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265

Tel: +81-3-6301-3066 Fax: +81-3-6301-3060



European Federation of Pharmaceutical
Industries and Associations

Ole Mølskov Bech, Chairman of EFPIA Japan said: “I would like to express our appreciation to all the organizations that participated in our PASE Awards program. Selecting the winners of the Grand Award was extremely challenging because the activities of all the patient organizations that applied were diverse in terms of disease areas and scale. EFPIA Japan aims to realize a patient-centered medical environment by supporting patient group activities to protect the environment where patients in Japan can continue to receive better treatment.”

#

About the EFPIA Japan Patient Organization Support Program “PASE”

“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program established in 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE was conceived to further encourage patient group activities in Japan, and to support the healthcare environment surrounding patients to evolve, so that it better reflects patients’ voices and patient needs. As part of PASE, EFPIA Japan decided to conduct the PASE Awards, in which grants of 1.45 million yen this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).

http://efpia.jp/link/1706_Notification_EFPIA_PASE_JP.pdf.

About the third “PASE Award”

New medicines that give patients hope for treatment are created by sustained investment in innovation¹, and various new drugs approved in Japan have positively changed patients’ life. However, due to drastic reform of the drug pricing system in recent years, there is concern that research and development of medicines in Japan is being delayed, which will lead to the re-emergence of the “drug lag”². For the third PASE Award, based on the potential impact on patients due to such environmental changes that year, “patient group activities to protect the environment so that patients can continue to receive better treatment” was selected as an application theme. The third PASE Awards invited active patient groups with legal entity status to submit plans between May 29 and July 26 to utilize the PASE grant in Japan. The draft plans were reviewed and selection was based on four evaluation criteria: “Having a clear purpose as a patient group and clear goals with KPIs?”, “Showing concrete deliverables for achieving purpose in past activities”, “Having a specific implementation plan of activity for using grants (including how to use grants)”, “Being able to cooperate in disseminating the results of activities using grants (Allowing for posting on EFPIA Japan website, notification and reporting on their own website)”. The two organizations that won the Grand Award were each offered a grant of 500,000 yen and invited to attend the presentation ceremony on 8 November last year. The three groups that won the Honor Award were offered a grant of 150,000 yen.



European Federation of Pharmaceutical
Industries and Associations

The third PASE Final Selection Committee Members

Dr. Ole Mølskov Bech (EFPIA, Chair)
Mr. Thorsten Poehl (EFPIA, Vice Chair)
Ms. Heike Prinz (EFPIA, Vice Chair)
Mr. Paul Lirette (EFPIA, Board member)
Ms. Kana Matsumura (Chair of Governance and Legal Committee)
Mr. Taro Kondo (Advisor, Tokyo Medical Association)

About the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan

EFPIA Japan, established in April 2002, represents 23 R&D-based European pharmaceutical companies operating in the Japanese market. Combined sales from the EFPIA member companies account for approximately 22% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “contribute to healthcare and patients in Japan through the rapid introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen communication with policymakers for the improvement of Japanese healthcare.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)

EFPIA, headquartered in Brussels, the capital of Belgium, represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people as well as contribute to the economy. Our vision is for a healthier future based on prevention, innovation, access to new treatments and better outcomes for patients.

Details can be found below.

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

Inquiries to:

Hitoshi Fujita, Public Relations Committee, EFPIA Japan

Novartis Pharma K.K.

1-23-1 Toranomom, Minato-ku, Tokyo 105-6333

TEL: 090-9837-4326

Mail: hitoshi.fujita@novartis.com

Miki Okada, Access Committee in charge of PASE, EFPIA Japan



European Federation of Pharmaceutical
Industries and Associations

GlaxoSmithKline K.K.

Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052

TEL : 070-3543-2224

Mail: miki.x.okada@gsk.com